AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 305.8 USD | +1.59% |
|
-0.01% | +6.17% |
| 28/05 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
| 28/05 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
| Sales 2024 * | 33B 2,742B | Sales 2025 * | 33.96B 2,822B | Capitalization | 164B 13,634B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.13B 343B | Net income 2025 * | 6.52B 542B | EV / Sales 2024 * | 6.44 x |
| Net Debt 2024 * | 48.6B 4,039B | Net Debt 2025 * | 43.61B 3,624B | EV / Sales 2025 * | 6.12 x |
| P/E ratio 2024 * |
38.6
x | P/E ratio 2025 * |
24.8
x | Employees | 26,700 |
| Yield 2024 * |
3.02% | Yield 2025 * |
3.27% | Free-Float | 99.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amgen Inc.
More recommendations
More press releases
More news
| 1 day | +1.59% | ||
| 1 week | -0.01% | ||
| Current month | -0.02% | ||
| 1 month | +9.85% | ||
| 3 months | +9.09% | ||
| 6 months | +12.24% | ||
| Current year | +6.17% |
1 week
295.49
305.90
1 month
295.49321.44
Current year
260.68329.72
1 year
215.32329.72
3 years
198.64329.72
5 years
170.56329.72
10 years
114.93329.72
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/01 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/19/23 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/17/03 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/16/14 |
Robert Williams
BRD | Director/Board Member | 75 | 17/14/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +14.89% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 305.8 | +1.61% | 4,488,874 |
| 30/24/30 | 301 | +1.56% | 2,727,281 |
| 29/24/29 | 296.4 | -1.27% | 2,475,871 |
| 28/24/28 | 300.2 | -1.85% | 2,636,709 |
Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST
More quotes
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.17% | 164B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| -0.45% | 162B |
- Stock Market
- Equities
- AMGN Stock
